The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score

Autor:	Atsushi Ogura, Toshiki Mukai, Masato Nagino, Yoshihiko Yonekawa, Yukihiro Yokoyama, Kay Uehara, Tomoki Ebata, Yasuhiro Kodera, Takashi Mizuno, Toshisada Aiba
Rok vydání:	2020
Předmět:	0301 basic medicine Oncology medicine.medical_specialty Multivariate analysis Colorectal cancer medicine.medical_treatment Population Subgroup analysis 03 medical and health sciences 0302 clinical medicine Surgical oncology Internal medicine medicine Hepatectomy Humans education Retrospective Studies Chemotherapy education.field_of_study Centimeter business.industry Liver Neoplasms Hematology General Medicine medicine.disease Neoadjuvant Therapy Tumor Burden Treatment Outcome 030104 developmental biology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Surgery Colorectal Neoplasms business
Zdroj:	International Journal of Clinical Oncology. 26:126-134
ISSN:	1437-7772 1341-9625
Popis:	The indications for neoadjuvant chemotherapy (NAC) in resectable colorectal liver metastases (CRLMs) remain unclear. Tumor burden score (TBS) is a prognostic tool based on tumor size and number of tumors. However, its utility in the NAC setting for initially resectable CRLM has never been investigated. TBS is a distance from the origin on a Cartesian plane to the coordinates (x, y) = (tumor size in centimeter, number of tumors). TBS
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7577a947e0f7f036a99c025e008a04ad https://doi.org/10.1007/s10147-020-01793-9 Zobrazit plný text záznamu Full text from SpringerLink